Great West Life Assurance Co. Can reduced its stake in Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) by 24.8% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 160,902 shares of the biopharmaceutical company’s stock after selling 53,107 shares during the period. Great West Life Assurance Co. Can owned 0.07% of Alexion Pharmaceuticals worth $19,556,000 as of its most recent filing with the SEC.

Other hedge funds and other institutional investors also recently bought and sold shares of the company. Guardian Life Insurance Co. of America increased its stake in shares of Alexion Pharmaceuticals by 0.7% in the first quarter. Guardian Life Insurance Co. of America now owns 865 shares of the biopharmaceutical company’s stock valued at $105,000 after buying an additional 6 shares during the last quarter. Meeder Asset Management Inc. acquired a new stake in shares of Alexion Pharmaceuticals during the first quarter valued at approximately $111,000. Independent Portfolio Consultants Inc. increased its stake in shares of Alexion Pharmaceuticals by 46.9% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,065 shares of the biopharmaceutical company’s stock valued at $129,000 after buying an additional 340 shares during the last quarter. Huntington National Bank increased its stake in shares of Alexion Pharmaceuticals by 1,084.6% in the second quarter. Huntington National Bank now owns 1,078 shares of the biopharmaceutical company’s stock valued at $131,000 after buying an additional 987 shares during the last quarter. Finally, FUKOKU MUTUAL LIFE INSURANCE Co increased its stake in shares of Alexion Pharmaceuticals by 10.0% in the first quarter. FUKOKU MUTUAL LIFE INSURANCE Co now owns 1,100 shares of the biopharmaceutical company’s stock valued at $133,000 after buying an additional 100 shares during the last quarter. Institutional investors and hedge funds own 94.37% of the company’s stock.

Shares of Alexion Pharmaceuticals, Inc. (ALXN) opened at 136.64 on Friday. Alexion Pharmaceuticals, Inc. has a 52-week low of $96.18 and a 52-week high of $145.41. The company has a 50 day moving average price of $125.22 and a 200-day moving average price of $122.56. The firm has a market cap of $30.50 billion, a P/E ratio of 59.25 and a beta of 1.41.

Alexion Pharmaceuticals (NASDAQ:ALXN) last posted its earnings results on Thursday, July 27th. The biopharmaceutical company reported $1.56 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.08 by $0.48. Alexion Pharmaceuticals had a net margin of 15.31% and a return on equity of 12.47%. The company had revenue of $912 million for the quarter, compared to analyst estimates of $846.15 million. During the same quarter in the prior year, the business posted $1.13 EPS. The firm’s revenue was up 21.1% compared to the same quarter last year. On average, analysts expect that Alexion Pharmaceuticals, Inc. will post $5.55 earnings per share for the current fiscal year.

ILLEGAL ACTIVITY WARNING: This news story was first reported by Daily Political and is the sole property of of Daily Political. If you are accessing this news story on another domain, it was stolen and reposted in violation of U.S. and international copyright and trademark law. The legal version of this news story can be accessed at https://www.dailypolitical.com/2017/08/06/great-west-life-assurance-co-can-sells-53107-shares-of-alexion-pharmaceuticals-inc-alxn.html.

Several analysts recently commented on ALXN shares. TheStreet raised Alexion Pharmaceuticals from a “c” rating to a “b-” rating in a research note on Friday, July 14th. Stifel Nicolaus reaffirmed a “buy” rating and set a $157.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Leerink Swann reaffirmed a “buy” rating on shares of Alexion Pharmaceuticals in a research note on Tuesday, May 23rd. Deutsche Bank AG dropped their price objective on Alexion Pharmaceuticals from $160.00 to $153.00 and set a “buy” rating on the stock in a research note on Thursday, May 25th. Finally, Goldman Sachs Group, Inc. (The) reaffirmed a “buy” rating and set a $158.00 price objective on shares of Alexion Pharmaceuticals in a research note on Wednesday, May 24th. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and three have assigned a strong buy rating to the stock. Alexion Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $156.89.

In related news, Director Ann M. Veneman sold 700 shares of the company’s stock in a transaction dated Monday, July 31st. The shares were sold at an average price of $137.74, for a total value of $96,418.00. Following the sale, the director now owns 6,315 shares in the company, valued at approximately $869,828.10. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director Bros. Advisors Lp Baker bought 1,348,955 shares of the stock in a transaction that occurred on Wednesday, June 14th. The stock was acquired at an average price of $116.32 per share, for a total transaction of $156,910,445.60. The disclosure for this purchase can be found here. Insiders purchased a total of 2,019,734 shares of company stock worth $235,606,846 in the last 90 days. 4.35% of the stock is currently owned by company insiders.

About Alexion Pharmaceuticals

Alexion Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutic products. The Company’s products include Soliris (eculizumab), Strensiq (asfotase alfa) and Kanuma (sebelipase alfa). The Company’s clinical development programs include Soliris (eculizumab), cPMP (ALXN1101), SBC-103, ALXN1210 (IV) and ALXN1210 (Subcutaneous).

Institutional Ownership by Quarter for Alexion Pharmaceuticals (NASDAQ:ALXN)

Receive News & Ratings for Alexion Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alexion Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.